MicroRNA-27a regulates the viability, migration and invasion of human skin cancer cells by targeting MAPK7
More details
Hide details
Department of Dermatology, The First People’s Hospital of Fuyang Hangzhou, Hangzhou, China
Department of Gynaecology, The First People’s Hospital of Fuyang Hangzhou, Hangzhou, China
Department of Pathology, The First People’s Hospital of Fuyang Hangzhou, Hangzhou, China
Submission date: 2020-02-09
Final revision date: 2020-03-20
Acceptance date: 2020-03-28
Online publication date: 2020-06-12
This study was undertaken to determine the expression profile of microRNA-27a (miR-27a) in human skin cancer and to assess its effects on cell viability, migration and invasion.

Material and methods:
Expression analysis was performed by qRT-PCR. Transfections were carried out using Lipofectamine 2000 reagent. AO/EB, DAPI, and Annexin V/PI staining was used for detection of apoptosis. Western blot analysis was performed to detect protein expression.

The results showed up to 7-fold upregulation of miR-27a in skin cancer tissues and up to 5-fold upregulation in skin cancer cell lines. Inhibition of miR-27a resulted in depletion of A431 cell viability as revealed by MTT assay. Phase-contrast microscopy and AO/EB assay showed signs of apoptosis in A431 cells. Immunohistochemical analysis showed reduction of the Bcl-2, p53 and ki-67 expression in A431 cells. Western blot analysis showed an increase in Bax and caspase-3 and a decrease in Bcl-2 protein expression. The wound healing and transwell assays revealed a remarkable decline of cell migration and invasion upon miR-27a inhibition. The bioinformatics and luciferase assays showed that miR-27a targets MAPK7. The Western blot analysis showed that MAPK7 was significantly downregulated in all skin cancer cells. Nonetheless, the expression of MAPK7 was significantly decreased upon miR-27a inhibition. Furthermore, MAPK7 overexpression increased the viability of A431 cells. However, MAPK1 silencing could avoid the suppressive effects of miR-27a inhibition on A431 cells.

The evidence suggests that miR-27a may find use in the treatment of skin cancer and warrants further investigation.